Importantly, the suppression of ILC3s by Treg cells contributes to repressing ILC3-mediated colitis, indicating that promoting the function of Treg cells or limiting the activity of CX3CR1+ macrophages would be a promising therapeutic option for treatment of IBD [106]. Here, CX3CR1 is linked to inflammatory bowel disease.